Yesterday, the Food and Drug Administration's (FDA) advisory committee met to discuss Merck's (MRK 0.27%) experimental insomnia drug Suvorexant. While the committee did agree that the drug was effective at lower doses, there were some concerns over the side-effects associated with the medication at higher doses. In the following video, health-care analyst Max Macaluso discusses the results of the meeting, and how the ultimate FDA decision on Suvorexant can impact Merck's stock.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.